Effects of pitavastatin (LIVALO tablet) on the estimated glomerular filtration rate (eGFR) in hypercholesterolemic patients with chronic kidney disease, -sub-analysis of the LIVALO effectiveness and safety (LIVES) study

Journal of Atherosclerosis and Thrombosis

Volumn 17, Issue 6, 2010, Pages 601-609

  Kimura, Kenjiro ^a   Shimano, Hitoshi ^b   Yokote, Koutaro ^c   Urashima, Mitsuyoshi ^d   Teramoto, Tamio ^e  

^a ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

^c CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Estimate of glomerular filtration rate; HMG COA reductase inhibitor; Statin; Urinary protein

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PITAVASTATIN; TRIACYLGLYCEROL; QUINOLINE DERIVATIVE;

ADULT; AGED; ANALYSIS OF VARIANCE; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; COMORBIDITY; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLOMERULUS FILTRATION RATE; HEART DISEASE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; KIDNEY FUNCTION; LIPID BLOOD LEVEL; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MYOPATHY; POSTMARKETING SURVEILLANCE; PROTEINURIA; SMOKING; TABLET; BLOOD; DRUG EFFECTS; INFORMATION PROCESSING; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOPHYSIOLOGY; RENAL INSUFFICIENCY, CHRONIC;

AGED; CHOLESTEROL, HDL; DATA COLLECTION; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROTEINURIA; QUINOLINES; RENAL INSUFFICIENCY, CHRONIC;

EID: 77954714775     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.3764     Document Type: Article

References (25)

1. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, Hogg RJ, Perrone RD, Lau J, Eknoyan G: National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med, 2003; 139: 137-147
2. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med, 2004; 351: 1296-1305
3. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spinosa DJ, Wilson PW: Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension, 2003; 42: 1050-1065
4. Shepherd J, Kastelein JJ, Bittner V, Deedwania P, Breazna A, Dobson S, Wilson DJ, Zuckerman A, Wenger NK: Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study. J Am Coll Cardiol, 2008; 51: 1448-1454
5. Imai E, Horio M, Iseki K, Yamagata K, Watanabe T, Hara S, Ura N, Kiyohara Y, Hirakata H, Moriyama T, Ando Y, Nitta K, Inaguma D, Narita I, Iso H, Wakai K, Yasuda Y, Tsukamoto Y, Ito S, Makino H, Hishida A, Matsuo S: Prevalence of chronic kidney disease (CKD) in the Japanese general population predicted by the MDRD equation modified by a Japanese coefficient. Clin Exp Nephrol, 2007; 11: 156-163
6. Clinical practice guidebook for diagnosis and treatment of chronic kidney disease 2009, pp 9, Tokyoigakusha, Tokyo, 2009
7. Shepherd J, Kastelein JJ, Bittner V, Deedwania P, Breazna A, Dobson S, Wilson DJ, Zuckerman A, Wenger NK: Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study. Clin J Am Soc Nephrol, 2007; 2: 1131-1139
8. Atthobari J, Brantsma AH, Gansevoort RT, Visser ST, Asselbergs FW, van Gilst WH, de Jong PE, de Jong-van den Berg LT: The effect of statins on urinary albumin excretion and glomerular filtration rate: results from both a randomized clinical trial and an observational cohort study. Nephrol Dial Transplant, 2006; 21: 3106-3114
9. Kurihara Y, Douzono T, Kawakita K, Nagasaka Y: A largescale, long-term, prospective post-marketing surveillance of pitavastatin (LIVALO Tablet)-LIVALO effectiveness and safety (LIVES) Study -. Jpn Pharmacol Ther, 2008; 36: 709-731
10. Teramoto T, Shimano H, Yokote K, Urashima M: Effects of Pitavastatin (LIVALO Tablet) on High Density Lipoprotein Cholesterol (HDL-C) in Hypercholesterolemia-Sub-analysis of LIVALO Effectiveness and Safety (LIVES) Study. J Atheroscler Thromb, 2009; 16: 654-661
11. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A: Revised Equations for Estimated GFR From Serum Creatinine in Japan. Am J Kidney Dis, 2009; 53: 982-992
12. National Kidney Foundation: K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis, 2002; 39 (2 Suppl 1): S1-266
13. Freidewald WT, Levy RI, Fredrikson DS: Estimation of the concentration of low density cholesterol in plasma without the use of a centrifuge. Clin Chem, 1972; 18: 449-502
14. Imai E, Horio M, Yamagata K, Iseki K, Hara S, Ura N, Kiyohara Y, Makino H, Hishida A, Matsuo S: Slower decline of glomerular filtration rate in the Japanese general population: a longitudinal 10-year follow-up study. Hypertens Res, 2008; 31: 433-441
15. Verma A, Ranganna KM, Reddy RS, Verma M, Gordon NF: Effect of rosuvastatin on C-reactive protein and renal function in patients with chronic kidney disease. Am J Cardiol, 2005; 96: 1290-1292
16. Athyros VG, Mikhailidis DP, Liberopoulos EN, Kakafika AI, Karagiannis A, Papageorgiou AA, Tziomalos K, Ganotakis ES, Elisaf M: Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study. Nephrol Dial Transplant, 2007; 22: 118-127
17. van Dijk MA, Kamper AM, van Veen S, Souverijn JH, Blauw GJ: Effect of simvastatin on renal function in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant, 2001; 16: 2152-2157
18. Tonelli M, Moyé L, Sacks FM, Cole T, Curhan GC: Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. J Am Soc Nephrol, 2003; 14: 1605-1613
19. Nakamura T, Sugaya T, Kawagoe Y, Ueda Y, Osada S, Koide H: Effect of pitavastatin on urinary liver-type fatty acid-binding protein levels in patients with early diabetic nephropathy. Diabetes Care, 2005; 28: 2728-2732
20. Liang XM, Otani H, Zhou Q, Tone Y, Fujii R, Mune M, Yukawa S, Akizawa T: Renal protective effects of pitavastatin on spontaneously hypercholesterolaemic Imai Rats. Nephrol Dial Transplant, 2007; 22: 2156-2164
21. Athyros VG, Kakafika AI, Papageorgiou AA, Pagourelias ED, Savvatianos SD, Elisaf M, Karagiannis A, Tziomalos K, Mikhailidis DP: Statin-Induced Increase in HDL-C and Renal Function in Coronary Heart Disease Patients. Open Cardiovasc Med J, 2007; 1: 8-14
22. Robbesyn F, Augé N, Vindis C, Cantero AV, Barbaras R, Negre-Salvayre A, Salvayre R: High-density lipoproteins prevent the oxidized low-density lipoprotein-induced epidermal [corrected] growth factor receptor activation and subsequent matrix metalloproteinase-2 upregulation. Arterioscler Thromb Vasc Biol, 2005; 25: 1206-1212
23. Nakamura H, Mizuno K, Ohashi Y, Yoshida T, Hirao K, Uchida Y: Pravastatin and cardiovascular risk in moderate chronic kidney disease. Atherosclerosis, 2009; 206: 512-517
24. Zhang Z, Shahinfar S, Keane WF, Ramjit D, Dickson TZ, Gleim GW, Mogensen CE, de Zeeuw D, Brenner BM, Snapinn SM: Importance of baseline distribution of proteinuria in renal outcomes trials: lessons from the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study. J Am Soc Nephrol, 2005; 16: 1775-1780
25. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR: Development and progression of nephropathy in type 2 diabetes:the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int, 2003; 63: 225-232